Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Novo Nordisk and BioMarin announced strategic partnerships to integrate artificial intelligence into their drug discovery pipelines, aiming to accelerate candidate identification and reduce development costs. Novo Nordisk highlighted a collaboration with a leading AI firm to model peptide therapeutics, while BioMarin disclosed an internal AI platform for rare‑disease target validation. In parallel, Bristol Myers Squibb appointed a senior neurology executive from Eisai to lead its emerging neuroscience portfolio, signaling a push into neuro‑degenerative therapies. The moves reflect a broader industry shift toward data‑driven R&D and talent acquisition to capture high‑growth therapeutic areas.
New York Sues Ex-Emergent CEO over Insider Trading During Vaccine Manufacturing Struggle
New York Attorney General sued the former chief executive of Emergent BioSolutions, alleging he engaged in insider trading while the company grappled with contamination problems at its Baltimore plant that delayed AstraZeneca’s COVID‑19 vaccine production. Prosecutors claim the executive sold...
Inside Fosun Pharma's Ambition to Reach Outside of China
Shanghai‑based Fosun Pharmaceutical is accelerating its transformation from a domestic generic manufacturer into a global innovator. The group has earmarked billions of dollars for overseas R&D hubs, strategic biotech partnerships and a new $2.5 billion bond to fund its expansion. Recent...
Alfasigma Gains Neuro Treatment; BridgeBio Offers $550M in Notes
Alfasigma has secured worldwide rights to a parenteral formulation of adibelivir for the treatment of HSV encephalitis, an ultra‑rare neurological condition. The agreement positions Alfasigma to commercialize the therapy across major markets. Meanwhile, BridgeBio announced a $550 million senior unsecured note...
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
The U.S. Food and Drug Administration will meet with Novo Nordisk early this year to review remediation progress at its Indiana manufacturing site, which has been under heightened scrutiny after contamination and production setbacks. The meeting follows a series of...
Ocugen Touts Phase 2 Data for Eye Disease Gene Therapy
Ocugen announced positive interim Phase 2 data for its geographic atrophy (GA) gene therapy, a leading cause of vision loss in age‑related macular degeneration. The trial, though limited to a small patient cohort, demonstrated measurable improvements in retinal function and...
J&J Reports Positive Phase 3 Data for Tecvayli in Earlier Blood Cancer Setting
Johnson & Johnson announced that its bispecific antibody Tecvayli (teclistamab) achieved a statistically significant overall survival benefit in a Phase 3 trial evaluating an earlier‑line setting for multiple myeloma. The study reported a hazard ratio of 0.68 for death and extended...
Novo Nordisk Foundation to Inject $850M+ Into BioInnovation Institute Through 2035
The Novo Nordisk Foundation announced a commitment of 5.5 billion Danish kroner (approximately $857 million) to the BioInnovation Institute, a life‑science and deep‑tech incubator, with funding extending through 2035. The pledge aims to bolster the institute’s capacity to nurture early‑stage biotech and...
Scribe Therapeutics Plans to Test Cholesterol-Lowering Therapy This Summer
The request does not contain the full text of the article titled “Scribe Therapeutics plans to test cholesterol‑lowering therapy this summer,” only a brief placeholder and a sign‑up prompt. Without the substantive content, no executive summary can be generated.
Manufacturers Benefit as Pharma Customers Invest Back in US
Recent tariff and trade policy shifts that unsettled pharmaceutical firms in 2025 are now creating upside for U.S. manufacturers. Pharma companies are redirecting capital toward domestic production, spurring demand for contract manufacturing and equipment. This investment wave is expected to...
Jazz Sells Priority Review Voucher for $200M, Scoring Highest Price in a Decade
Jazz Pharmaceuticals announced the sale of a priority review voucher to an undisclosed buyer for $200 million, marking the highest price paid for such a voucher in a decade. The voucher, originally granted for developing a treatment for a neglected disease,...
Health Tech Funding Rounds Get Bigger when Andreessen Horowitz and General Catalyst Join
Rock Health’s latest report shows a handful of venture firms dominate health‑tech financing. When Andreessen Horowitz and General Catalyst join a round, the deal size expands dramatically, with average rounds climbing from roughly $30 million to $50 million. Together these two firms...
ImmunityBio's Anktiva Lung Cancer Data; Glaukos' Glaucoma Implant Sales Disappoint
ImmunityBio announced that its lymphocyte‑stimulating agent Anktiva, combined with checkpoint inhibitors, restored immune cells and produced objective responses in a non‑small‑cell lung cancer (NSCLC) study. The data suggest the combination could enhance the efficacy of existing immunotherapies. Meanwhile, Glaukos reported...
Thermo Fisher to Lay Off 421 Workers as It Winds Down Lab Product Site in North Carolina
Thermo Fisher Scientific announced it will phase out operations at its laboratory products facility in Asheville, North Carolina, laying off 421 workers. The shutdown is slated to be completed by the end of 2026, ending the site’s production of consumables...
#JPM26: Day 3 at the JP Morgan Healthcare Conference
Day three of the JPMorgan Healthcare Conference saw sessions winding down as investors turned their attention to key presentations, notably from Chinese contract research giant WuXi AppTec. The company used its slot to unveil a refreshed drug‑development platform and hint...
#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 Outlook
Chris Boerner, in his third year as Bristol Myers Squibb CEO, opened the JPMorgan Healthcare Conference with a forward‑looking Q&A on the company’s 2026 outlook. He outlined a $45 billion revenue target, driven by late‑stage oncology and immunology assets, while emphasizing...
FDA Delays Decision on Expanding Label for Travere's Kidney Disorder Drug
The FDA has extended its review of Travere Therapeutics’ kidney‑disorder drug by three months, pushing the expected decision past today’s deadline. The agency’s delay pertains to a pending label expansion for a rare renal condition, which could broaden the drug’s...
FDA Requests Flu Vaccine Label Updates to Include Febrile Seizure Risk
The U.S. Food and Drug Administration has asked manufacturers of six seasonal influenza vaccines to revise their product labels to explicitly mention the risk of febrile seizures. The directive follows emerging safety data linking certain flu shots, especially those administered...
FDA Asks Lilly, Novo to Remove Suicide Warnings From GLP-1 Labels
The FDA has asked Eli Lilly and Novo Nordisk to remove suicide‑related warnings from the labels of their GLP‑1 weight‑loss drugs. The warning, added in 2022 after isolated case reports, is being reconsidered following a thorough review of post‑marketing data. The agency...
HHS Ousts Vaccine Injury Panel Members as Reshaping Takes Hold
The U.S. Department of Health and Human Services removed several members from the Vaccine Injury Compensation Program’s advisory committee, signaling a significant reshaping of the panel. The ousted members were appointed during the previous administration and faced criticism for their...
Trump Administration Appears to Have Ended Its US Trade Probe Into Pharma
The U.S. Department of Commerce has reportedly concluded its Section 232 investigation into pharmaceutical imports, effectively ending the Trump administration’s trade probe. The decision means no new tariffs will be levied on foreign‑made medicines, averting a potential price shock for...
VantAI Gets $80M and New Name; Dynavax Discloses It Had Pre-Sanofi Suitor
VantAI, a Roivant‑incubated AI drug‑discovery startup, closed an $80 million seed round and announced a rebrand to Proxima. The funding, led by existing backers, is intended to accelerate its proprietary AI platform for early‑stage therapeutics. The round underscores growing investor appetite...
Who’s Afraid of OpenAI?
OpenAI’s accelerating pace of model development is prompting businesses to reconsider direct competition. Companies are weighing whether to build in‑house AI, partner with OpenAI, or adopt alternative strategies. The debate intensifies as OpenAI’s products become more embedded in enterprise workflows,...
Marea Takes Drug for Acromegaly to Phase 2
Marea Therapeutics announced that its experimental drug for acromegaly has entered Phase 2 clinical testing. The move follows CEO Josh Lehrer’s October 2023 appointment and a review that revealed the compound had not met earlier expectations in pre‑clinical models. The Phase 2...
Novartis Licenses Radiopharma Asset From Chinese Biotech for $50M Upfront
Novartis has agreed to pay $50 million upfront to license a peptide‑based radiopharmaceutical asset from China’s Zonsen PepLib Biotech. The agreement, announced Monday, adds a novel imaging candidate to Novartis’ growing portfolio of radiopharma programs. Zonsen PepLib, a biotech focused on...
#JPM26: Day 2 at the JP Morgan Healthcare Conference
Amgen announced on day two of the J.P. Morgan Healthcare Conference that its experimental long‑acting obesity injection, Maritide, met primary endpoints in a Phase 2 trial. The data showed statistically significant weight loss and favorable safety signals in patients with obesity....
Sentynl Gets the First US Approval for Rare Copper Absorption Disease
Sentynl Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its investigational therapy targeting Menkes disease, a rare and fatal genetic disorder of copper absorption. The approved product, branded Zycu..., is the first therapy in the...
Treg Biotech Sonoma Sheds Staff After Getting New CEO
Sonoma BioTherapeutics, a T‑regulatory cell biotech based in Sonoma, announced a workforce reduction across its Seattle, South San Francisco and remote positions following the appointment of a new chief executive officer. The cuts affect multiple departments as the company seeks...
Congress' Biotech Panel Pitches FDA Policy Upgrades to Help Performance
The National Security Commission on Emerging Biotechnology released a report urging the FDA to modernize its policies as biotech innovation outpaces regulation. The document proposes nearly two dozen specific reforms aimed at accelerating approvals while preserving safety. Recommendations include real‑time...
Pretzel Buys Rome and Its ‘Dark Genome’ Work
Pretzel Therapeutics announced the acquisition of Rome Therapeutics, a company specializing in “dark genome” research. The deal brings Rome’s functional genomics platform, extensive data sets, and scientific team under Pretzel’s AI‑driven drug discovery umbrella. Financial terms were not disclosed, but...
Nvidia-Partnered Startup Reveals AI-Generated Enzymes for Precise Gene Insertion
Basecamp Research, in partnership with Nvidia, unveiled a gene‑editing toolkit built from AI‑generated enzymes. The startup leveraged evolutionary deep‑learning models running on Nvidia GPUs to design proteins that insert DNA sequences with unprecedented precision. Early laboratory data indicate higher on‑target...
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
Novo Nordisk CEO Mike Doustad highlighted the explosive growth of telehealth‑driven GLP‑1 obesity drug sales. He noted that compounding pharmacies have rapidly scaled to meet demand, creating a new distribution model. Doustad argued that traditional pharma can learn from this...
At FDA's Request, Pfizer Helps Ease Shortage of Potential Autism Drug
The U.S. Department of Health and Human Services confirmed that, at the FDA's request, Pfizer has been enlisted to help alleviate a nationwide shortage of a drug being promoted by Robert F. Kennedy Jr.'s organization as a potential autism treatment....
FDA Lifts Partial Hold on Merck, Daiichi's Phase 3 Lung Cancer Study
The U.S. Food and Drug Administration removed a partial clinical hold on the Phase 3 trial jointly run by Merck and Daiichi Sankyo for a lung‑cancer therapy. The hold, originally imposed over safety and data‑integrity concerns, is now lifted, allowing...
Eisai Licenses Nuvation Lung Cancer Pill; Alnylam's Stock Dips After Sales Data Report
Eisai announced a licensing agreement with Nuvation Bio to develop a novel lung‑cancer pill, securing exclusive rights and an upfront cash payment plus milestone fees. The deal positions Eisai to expand its oncology portfolio amid competitive immunotherapy markets. Meanwhile, Alnylam...
AbbVie Jumps Into PD-1xVEGF Bispecific Race, Pays $650M Upfront to RemeGen
AbbVie announced a $650 million upfront deal with Chinese biotech RemeGen to acquire a bispecific antibody that simultaneously blocks PD‑1 and VEGF, marking its entry into the fast‑growing PD‑1×VEGF space. The agreement, unveiled at the JPMorgan Healthcare Conference, includes additional milestone...
Eli Lilly, Nvidia Sign Five-Year, up to $1B Deal for AI Laboratory
Pharmaceutical giant Eli Lilly and chipmaker Nvidia have sealed a five‑year agreement worth up to $1 billion to create an AI laboratory focused on drug discovery. The partnership builds on an earlier pact to construct pharma’s most powerful supercomputer, extending Nvidia’s hardware...
FDA Again Rejects Atara, Pierre Fabre's Cell Therapy for Epstein-Barr Virus
The U.S. Food and Drug Administration has again refused to approve Atara Bio’s EBV‑specific T‑cell therapy, a treatment developed with French partner Pierre Fabre for post‑transplant lymphoproliferative disorder (PTLD). The agency cited insufficient clinical data and unresolved safety concerns, prompting Atara...
Arkin Capital Raises $100M to Back a Dozen Early-Stage Biotechs
Arkin Capital has closed a $100 million third early‑stage biotech fund, aimed at backing 10 to 12 nascent drug‑development companies. The Israel‑based venture firm plans to deploy the capital across a portfolio of early‑stage therapeutics, focusing on innovative platforms and unmet...
#JPM26: Moderna CEO Bancel Talks Deals, Flu and RSV Strategy
Moderna CEO Stéphane Bancel told JPMorgan analysts that the company’s deals team has closed several partnership agreements in the first quarter, accelerating its pipeline beyond COVID‑19. He outlined a dual‑track strategy for the upcoming flu season, emphasizing a next‑generation quadrivalent...
Novartis, SciNeuro to Work Together on Preclinical Amyloid-Targeting Drug for Alzheimer’s
Novartis is committing $165 million upfront to license a pre‑clinical amyloid‑targeting program from SciNeuro. The partnership will jointly advance the candidate through IND‑enabling studies and later clinical trials. Both companies aim to develop a disease‑modifying Alzheimer’s therapy that can address the...
Signal Pulse Poll: What's the Mood Going Into JPM?
Endpoints has launched a daily Pulse Poll to capture biopharma sentiment ahead of the J.P. Morgan Healthcare Conference 2024. The survey asks participants to compare current mood with last year, assess the 2026 risk‑reward balance, and identify the most critical...
Private and Public Biotechs Go on $4.9B Funding Spree Ahead of JPM
In the first full week of January, biotech companies collectively raised about $4.9 billion, marking a rapid funding surge ahead of the J.P. Morgan Healthcare Conference. Private‑stage firms attracted roughly $3.2 billion, while publicly listed biotechs secured around $1.7 billion through secondary offerings...
Biotech's 2026 Outlook: Six Questions for the Year Ahead
The 2026 biotech outlook hinges on six pivotal questions that will shape the industry’s trajectory. After a turbulent 2025 marked by regulatory shifts, financing volatility, and rapid scientific advances, stakeholders are reassessing strategies. Key themes include FDA reform, capital availability,...
Mirador Raises $250M, with Plans to Become an Immunology Powerhouse
Mirador Therapeutics announced a $250 million Series B financing round, led by top venture capital firms. The capital will accelerate its precision‑medicine platform aimed at immune‑mediated diseases. Mirador plans to broaden its R&D pipeline, establish new manufacturing capacity, and recruit leading...
Genentech CEO Says Pharmacy Benefit Manager Shift Will Save $70M
Genentech announced it will move its pharmacy benefit coverage from a major PBM to a privately‑held entity it controls, aiming to capture savings and increase transparency. The shift is projected to generate about $70 million in annual cost reductions for the...
Hair Growth Biotech Veradermics Files for IPO to Fund Oral Rogaine
Veradermics, a biotech focused on an oral formulation of the hair‑growth drug Rogaine, has filed an S‑1 to launch an initial public offering. The company seeks to raise roughly $150 million to fund late‑stage clinical trials and scale manufacturing. An oral...
How Merck Plans to Set a Buffer for Keytruda's Patent Cliff
Merck’s blockbuster immunotherapy Keytruda is approaching a major patent cliff, with its primary U.S. patent set to expire in 2028. To blunt the anticipated revenue erosion, the company is deploying a multi‑pronged buffer strategy that includes filing for patent extensions,...
Orca Adds $250M in Financing to Back Launch of T Cell Therapy
Orca Bio announced it has raised $250 million in new financing to support the commercial launch of its T‑cell therapy designed to treat complications from allogeneic stem cell transplants. The capital infusion comes from a mix of venture capital firms and...
Novartis to Build Fourth US Radiotherapy Factory in Florida
Novartis announced the construction of its fourth U.S. radiotherapy manufacturing facility, a 35,000‑square‑foot plant in Winter Garden, Florida. The new site is part of the company’s broader $23 billion pledge to expand domestic production across the United States. The factory will...